Social Media Buzz 4/26/12
Bayer CEO Marijn Dekkers says organic growth is his priority, but does not rule out acquisitions in the coming years.
Onyx Pharmaceuticals announces that an FDA advisory committee will review carfilzomib for the treatment of relapsed and refractory multiple myeloma
Repligen reports positive results from Phase I clinical trial of RG3039 for Spinal Muscular Atrophy. However, it expects the FDA to reject its MRI imaging agent.
Valeritas, an insulin-delivery device maker, has replaced its complicated client/server CRM with a cloud-based Veeva CRM and Veeva iRep for the iPad.